Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, B-Cell × Etoposide × Clear all

Phase

Phase 2 13 Phase 1/2 7 Phase 1 7 Phase 3 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma 6 Leukemia 6 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Non-Hodgkin 4 Recurrence 3 Sezary Syndrome 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Follicular 2 Leukemia, T-Cell 2 Leukemia, Myeloid, Acute 2 Leukemia, Biphenotypic, Acute 2 Congenital Abnormalities 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Teratoma 1 Small Cell Lung Carcinoma 1 Seminoma 1 Sarcoma, Ewing 1 Retinoblastoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroblastoma 1 Neoplasms 1 Myeloproliferative Disorders 1

Interventions

Rituximab 2 loncastuximab tesirine 1 etoposide phosphate 1 blinatumomab 1 Tubercidin 1 Immunotherapy, Adoptive 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05991388 2026-02-20

Glo-BNHL

University of Birmingham

Phase 2/3 Recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡